Resources

Clinical trials are vital to drug development but often face challenges such as slow patient recruitment, high costs, and suboptimal trial designs. Today, artificial intelligence (AI) and real-world data (RWD) are transforming this process by optimizing trial protocols, enhancing recruitment, and accelerating timelines.  

The healthcare industry is on the cusp of transformation. Artificial intelligence (AI)-driven insights, real-world evidence (RWE)-backed regulatory decisions, and a new era of patient-centricity are already shaping the next chapter of healthcare.

Clinical trials are the backbone of medical advancements, yet they often face significant hurdles in their final stages.

In the evolving landscape of clinical research, the era of one-size-fits-all clinical trials is firmly behind us. Regulatory bodies and industry leaders alike recognize the necessity of diverse representation in trials to ensure that medical treatments are effective for all populations.

Multiple myeloma (MM) is a rare and complex blood cancer that affects plasma cells in the bone marrow. These malignant cells accumulate and interfere with normal blood cell production, leading to complications such as anemia, kidney dysfunction, bone lesions, and increased susceptibility to infections.

The integration of digital technology is transforming clinical research, improving the efficiency of trial design and execution. A key innovation in this space is the digital waiting room, which leverages real-world data (RWD) and artificial intelligence (AI) to enhance the critical “last mile” of a trial—when sites are activated, and patient recruitment begins. 

SCOPE 2025, held from February 3-6 in Orlando, Florida, brought together over 4,500 leaders in clinical operations and research to discuss the latest advancements in clinical trial innovation, planning, management, and operations

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.   

In a rapidly evolving healthcare landscape, artificial intelligence (AI) is emerging as a transformative force in drug development and clinical research. With the average cost of bringing a new drug to market soaring to $1.3 billion and a low probability of success, the stakes for innovation have never been higher.

HES is a group of rare disorders characterized by persistent hypereosinophilia in blood and/or tissues, causing organ damage/dysfunction; real-world treatment patterns of patients with I-HES or L-HES remain unknown.

Adverse Drug Events (ADEs) or Adverse Drug Reactions (ADRs) continue to be a concern both in new and existing medicines. According to Medication Safety Data published by the U.S. Centers for Disease Control and Prevention (CDC), ADEs cause more than 1.5 million emergency department (ED) visits each year and nearly 500,000 patients are hospitalized after these ED visits

In the dynamic world of healthcare, real-world data (RWD) and the real-world evidence (RWE) derived from it stand as a crucial pillar for informed insights and actions.